A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 22-28

  Wojtulewski, J A ^a   Schattenkirchner, M ^b   Barcelo P ^c   Le Loet X ^d   Bevis, P J R ^e   Bluhmki, E ^f   Distel, M ^f  

^a EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

^c Hosp Malalties de Reumatiques   (Spain)

^d Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^e BOEHRINGER INGELHEIM LTD   (United Kingdom)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Cyclooxygenase 2; Gastrointestinal; Meloxicam; Naproxen; Non steroidal anti inflammatory drug; Rheumatoid arthritis

Indexed keywords

CREATININE; HEMOGLOBIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; UREA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; UREA BLOOD LEVEL;

EID: 0029865433     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.22     Document Type: Article

References (21)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
2. Vane J. Towards a better aspirin. Nature 1994;367:215-6.
3. Vane JR, Botting RM. New insights into the mode and action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
4. Engelhardt G. Meloxicam. A potent inhibitor of COX-2. Data presented at the 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 6-10, 1994, p. 82.
5. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
6. Engelhardt G. Meloxicam:. lack of correlation between inhibition of PG biosynthesis in the inflammatory field and in the stomach. Magy Rheumatol 1991;32b(suppl.):354, abstract no. P4-277.
7. Stei P, Kruss B, Wiegleb J, Trach V. Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Br J Rheumatol 1996;35(suppl. 1): 44-50.
8. Fenton SF, Ryan JP, Bensen WG. A double-blind, crossover, multicenter study of piroxicam and naproxen in rheumatoid arthritis. Curr Ther Res 1988;44:1058-70.
9. Caldwell JR, Roth SH, Naproxen EC Study Group. A double blind study comparing the efficacy and safety of enteric coated naproxen to naproxen in the management of NSAID intolerant patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1994;21:689-95.
10. Lister BJ, Poland M, DeLapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993;95(suppl. 2A):25-95.
11. Arnett FC, Edworth SM, Block DA. The American Rheumatism Association 1987, revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1993;31:315-24.
12. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:1949.
13. Karch FE, Lasagna L. Adverse drug reactions. J Am Med Assoc 1975;234:1236-41.
14. Chuang-Stein C. Summarizing laboratory data with different reference ranges in multicentre clinical trials. Drug Inf J 1992;26:77-84.
15. Huskisson EC, Narjes H, Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994;Suppl 98:abstract no. 115.
16. Lund B, Distel M, Bluhmki E. A double-blind placebo controlled study of three different doses of meloxicam in patients with osteoarthritis (OA) of the knee. Scand J Rheumatol 1994;Suppl 98:abstract no. 117.
17. Whittle BJR, Vane JR. A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatoid drugs. Arch Toxicol 1984;Suppl 7:315-22.
18. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med 1987;147:2093-100.
19. Russel RL. Endoscopic evaluation of edotalac and naproxen and their relative effects on gastric and duodenal prostaglandins. Rheumatol Int 1990;10(suppl.):17-21.
20. Maniglia R, Schwartz AB, Moriber-Katz S. Non-steroidal anti-inflammatory nephrotoxicity. Ann Clin Lab Sci 1988;18:240-52.
21. Eriksson LO, Sturfelt G, Thysell H et al. Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med 1990;89:313-21.